Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: Evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients

Blood

Volumn 103, Issue 6, 2004, Pages 2121-2126

  Cugno, Massimo ^a   Cabibbe, Mara ^b   Galli, Monica ^b   Meroni, Pier Luigi ^b   Caccia, Sonia ^b   Russo, Rosaria ^b   Bottasso, Biarca ^b   Mannucci, Pier Mannuccio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; PHOSPHOLIPID ANTIBODY; PLASMINOGEN; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FETUS WASTAGE; FIBRINOLYSIS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DOMAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 1542373659     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2422     Document Type: Article

References (36)

1. Levine JS, Ware Branch D, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
2. McCrae KR, Feinstein DI, Cines DB. Antiphospholipid antibodies and antiphospholipid syndrome. In: Colman W, Hirsh J, Marder VJ, Clowes AW George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2001; 1339-1356.
3. Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost. 1992;65:516-520.
4. Ieko M, Sawada K, Koike T, et al. The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin Thromb Res. 1999;25:503-507.
5. Ieko M, Ichicawa K, Atsumi T, et al. Effects of beta 2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Haemost. 2000;26:85-90.
6. Cugno M., Cattaneo M., Bisiani G., Cabibbe M., Martinelli I. Absence of antibodies to tissue-type plaminogen activator in patients with previous deep vein thrombosis. Int J Clin Lab Res. 1998;28:72-73.
7. Cugno M., Dominguez M., Cabibbe M., et al. Antibodies to tissue-type plaminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol. 2000;108:871-875.
8. Wilson WA, Gharavi AE, Koike T, et al. Intemational consensus statement on preliminary classification criteria for definite antiphospholipld syndrome. Arthritis Rheum. 1999;42:1309-1311.
9. Brandt JT, Triplett DA Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
10. Exner T, Rickard KA, Kronenberg H. Sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol. 1978;40:143-151.
11. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russel viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986;68:869-874.
12. Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as screening and confirmatory test for detection of lupus anticoagulants. Thromb Res. 1992;67:355-365.
13. Triplett DA, Stocker KF, Unger GA, Bama LK. The textarin/ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost. 1993;6:925-931.
14. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol. 1985;62:738-744.
15. Harris EN, Gharavi AE, Hughes GRW. The anticardiolipin assay. In: Harris EN, Exner T, Hughes GRW, Asherson RA, eds. Phospholipid-binding antibodies. Boca Raton, FL: CRC Press; 1991:175-187.
16. Cugno M, Cicardi M, Colucci M, et al. Non neutralizing antibodies to tissue-type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost. 1996;76:234-238.
17. Martin U, Kohnert U, Stern A, Popp F, Fisher S. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Thromb Haemost. 1996;76:1096-1101.
18. 2-glycoprotein I and preserved during species' evolution. J Immunol. 1996;157:5732-5738.
19. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulants IgG's are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66 629-632.
20. 2-Glycoprotein I: target antigen for "antiphospholipid" antibodies: immunological and molecular aspects. Lupus. 1998;7(suppl 2):S5-S9.
21. Galli M, Confurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547.
22. Dominguez M, Cacoub P, de la Torre IG, Piette JC, Salazar-Paramo M, Anglès-Cano E. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. J Rheumatol. 2001;28:302-308.
23. Varela F, Anderson A, Dietrich G, et al. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci U S A. 1991;88:5917-5921.
24. Salazar-Paramo M, Garcia de la Torre I, Fritzler M, Loyau S, Angles-Cano E. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud phenomenon and thrombosis. Lupus. 1996;5:275-278.
25. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989;16:623-625.
26. 2-GPI and cardiolipin in patients with systemic lupus erythematosus and primary antiphospoholipid syndrome and their clinical associations. Rheumatology. 2001;40:1026-1032.
27. Puurunen M, Manttari M, Manninen V, Palosuo T, Vaarala O. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. Br J Haematol. 1998;100:374-379.
28. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. Philadelphia, PA: WB Saunders; 2000.
29. Munkata Y, Salto T, Matsuda K, et al. Detection of complement fixing antiphospoholipid antibodies in association with thrombosis. Thromb Haemost. 2000;83:728-731.
30. Hörkkö S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low-density lipoprotein. J Clin Invest. 1996;98: 815-825.
31. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211-220.
32. Bachmann F. The plasminogen plasmin enzyme system. In: Colman W, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2001:275-320.
33. Kolev K, Gombàs J, Vàradi B, et al. Immunoglobulin G from patients with the antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost. 2002;87:502-508.
34. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In Colman W, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2001:975-1002.
35. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation. 1997;95:1425-1432.
36. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology. 2003;207:29-36.